Cited by 66Dermatology and Skin DiseasesAdvancements in Transdermal Drug DeliveryContact Dermatitis and Allergies

Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms

Open access
Hou, Maihua, Sun, Richard, Hupe, Melanie, Kim, Peggy L., Park, Kyungho, Crumrine, Debra, Lin, Tzu‐Kai, Santiago, Juan Luis +3 more·2013·Experimental Dermatology

Abstract

The beneficial effects of certain herbal medicines on cutaneous function have been appreciated for centuries. Among these agents, chrysanthemum extract, apigenin, has been used for skin care, particularly in China, for millennia. However, the underlying mechanisms by which apigenin benefits the skin are not known. In this study, we first determined whether topical apigenin positively influences permeability barrier homoeostasis, and then the basis thereof. Hairless mice were treated topically with either 0.1% apigenin or vehicle alone twice daily for 9 days. At the end of the treatments, permeability barrier function was assessed with either an electrolytic water analyzer or a Tewameter. Our results show that topical apigenin significantly enhanced permeability barrier homoeostasis after tape stripping, although basal permeability barrier function remained unchanged. Improved barrier function correlated with enhanced filaggrin expression and lamellar body production, which was paralleled by elevated m RNA levels for the epidermal ABCA12. The m RNA levels for key lipid synthetic enzymes also were upregulated by apigenin. Finally, both cathelicidin‐related peptide and mouse beta‐defensin 3 immunostaining were increased by apigenin. We conclude that topical apigenin improves epidermal permeability barrier function by stimulating epidermal differentiation, lipid synthesis and secretion, as well as cutaneous antimicrobial peptide production. Apigenin could be useful for the prevention and treatment of skin disorders characterized by permeability barrier dysfunction, associated with reduced filaggrin levels and impaired antimicrobial defenses, such as atopic dermatitis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/exd.12102

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hou, M., Sun, R., Hupe, M., Kim, P. L., Park, K., Crumrine, D., Lin, T., Santiago, J. L., Mauro, T. M., Elias, P. M., & Man, M.
Affiliations
San Francisco VA Medical Center (US)
Corresponding author
Man, Mao‐Qiang
Venue
Experimental Dermatology
Publisher
Wiley
Published
2013-03
Volume
22
Issue
3
Pages
210-215
ISSN
  • 0906-6705 (ISSN-L)
  • 1600-0625
OpenAlex
W2092326765
Cited by
66
References
63
Citations by year
2026: 5 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 3 · 2013: 1
FWCI
5.87
Type
journal article
Language
en
Open access
Locations
  • Experimental Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR19089, AR051930, R01AR019098, R01AR051930)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
apigenin, chrysanthemum extract, epidermal permeability barrier, filaggrin, lamellar bodies, ABCA12, epidermal differentiation, antimicrobial peptides, human beta-defensin 3, tape stripping, atopic dermatitis, herbal medicine, topical application
MeSH terms
Epidermal Cells, Filaggrin Proteins, Administration, Topical, Animals, Cell Differentiation, Cell Membrane Permeability, Cells, Cultured, Dose-Response Relationship, Drug, Epidermis, Female, Homeostasis, Intermediate Filament Proteins, Mice, Hairless, Plant Extracts, Skin, Keratinocytes, ATP-Binding Cassette Transporters, beta-Defensins, Antimicrobial Cationic Peptides, Models, Animal, Chrysanthemum, Apigenin, Mice, Cathelicidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review